Dr. Almodovar Suarez is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Meadowmont Village Circle
Suite 202
Chapel Hill, NC 27517
Summary
- My approach to clinical care is based on compassion, respect and a team-based model. I work with wonderful and involved advanced practice providers and neurology residents with the objective of providing updated, evidence-based diagnostic and treatment advice. I strongly encourage patients to take a lead in their own care and consider them to be active members of our team. Questions about diagnostic and treatment strategies are essential for success of our model.
Education & Training
University of RochesterFellowship, Clinical Neurophysiology, 2010 - 2011
Boston University Medical CenterResidency, Neurology, 2007 - 2010
Virginia Commonwealth University Health SystemInternship, Internal Medicine, 2006 - 2007
University of Puerto Rico School of MedicineClass of 2006
Certifications & Licensure
NC State Medical License 2019 - 2025
NH State Medical License 2011 - 2019
NY State Medical License 2010 - 2012
VA State Medical License 2006 - 2007- American Board of Psychiatry and Neurology Neurology
- American Board of Psychiatry and Neurology Clinical Neurophysiology
Awards, Honors, & Recognition
- Award for Creative Expression of Human Values in Neurology: “Neurology and the Humanities: The Ghost of Gehrig”. Neurology. 2013 Jan 80(2): 223-224. American Academy of Neurology, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients Start of enrollment: 2021 Mar 30
- Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment Start of enrollment: 2021 Oct 28
- A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) Start of enrollment: 2020 Apr 15
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsNeurologic Injury After Sacral Neuromodulation.Angela S. Yuan, Jorge L. Almodovar, Elisabeth A. Erekson
Female Pelvic Medicine & Reconstructive Surgery. 2019-03-01 - 44 citationsElectrophysiologic features of SYT2 mutations causing a treatable neuromuscular syndromeRoger G. Whittaker, David N. Herrmann, Boglarka Bansagi, Bashar Awwad Shiekh Hasan, Robert Muni Lofra
Neurology. 2015-12-01 - 81 citationsSynaptotagmin 2 Mutations Cause an Autosomal-Dominant Form of Lambert-Eaton Myasthenic Syndrome and Nonprogressive Motor NeuropathyDavid N. Herrmann, Rita Horvath, Janet E. Sowden, Michael Gonzales, Avencia Sanchez-Mejias
American Journal of Human Genetics. 2014-09-04
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
